Results 171 to 180 of about 64,132 (259)

Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons

Advanced Genetics, Volume 7, Issue 2, June 2026.
This review highlights six genetic diseases of the bone, aiming to provide clinicians and researchers with updated information on their diagnosis and treatment. It also includes an assessment of common clinical and radiographic findings, along with pathophysiology related to diseases.
Colin Jones, Ambalangodage C. Jayasuriya
wiley   +1 more source

N-terminal proBNP adds prognostic value to high-sensitivity cardiac troponin I in elective thoracic surgery: an observational cohort study. [PDF]

BMJ Open
Alonso M, Popova E, De Miguel M, García-Osuna Á, Gonzalez-Tallada A, Ordoñez-Llanos J, Jauregui A, Trujillo JC, Martin Grande A, Martínez-Téllez E, Parera A, Planas G, Trujillo L, Butron D, Solà-Roca J, De Nadal M.   +15 more
europepmc   +1 more source

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy.
Alexander Carpinteiro, Christoph Kimmich, Despina Trajanova, Ute Hegenbart, Timon Hansen, Udo Holtick, Vera von Landenberg‐Roberg, Stephan Rainer Bohl, Raphael Teipel, Ivana von Metzler, Monika Engelhardt, Evgenii Shumilov, Maximilian Steinhardt, Hans Christian Reinhardt, Sara Oubari, Stefan Schönland   +15 more
wiley   +1 more source

Bioelectrical impedance analysis and physical function improved risk prediction for cardiac dysfunction in hemodialysis patients. [PDF]

Front Physiol
Zhang W, Yao L, Zhu Q, Lu J, Liu Q, Ding W.   +5 more
europepmc   +1 more source

Screening for HFpEF in pacemaker patients: Study design and protocol of the PM-HFpEF study. [PDF]

PLoS One
Santos E, Teixeira R, Almeida J, Fonseca P, Oliveira M, Gonçalves H, Primo J, Diaz S, Barros A, Vilela E, Sampaio F, Saraiva F, Oliveira M, de Carvalho RF.   +13 more
europepmc   +1 more source

Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial.

JAMA Cardiol
Lu H, Kosztin A, Claggett BL, Foà A, Pabón MA, Desai AS, Jhund PS, Henderson AD, Merkely B, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Amarante F, Saarinen R, De Sanctis Y, Glasauer A, McMurray JJV, Vaduganathan M, Solomon SD.   +21 more
europepmc   +1 more source

Mac-2 binding protein glycosylation isomer contributes to identify advanced Fontan-associated liver disease: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Kitsugi K, Hosoda Y, Murohisa G, Yoshizawa Y, Kimata M, Kobayashi Y, Unno S, Yamada Y, Takayanagi T, Kawata K.   +9 more
europepmc   +1 more source

The Role of Endothelin‐1 in Autoimmune Diseases: Mechanistic Insights and Therapeutic Targets

iNew Medicine, Volume 2, Issue 2, June 2026.
The Role of Endothelin‐1 in Autoimmune Diseases. NF‐κB: nuclear factor kappa‐B; MAPK: mitogen‐activated protein kinase; PI3K: phosphoinositide 3‐kinase; ROS: reactive oxygen species; CTGF: connective tissue growth factor; TGF‐β: transforming growth factor‐β.
Xun Gong, Zhenyu Wang, Suyin Yang, Kaige Gao, Xin Yang, Min Tang   +5 more
wiley   +1 more source

Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs. [PDF]

J Endocr Soc
Kamrul-Hasan ABM, Uday S, Nagendra L, Dutta D, Bhattacharya S, Pappachan JM, Ashraf AP.   +6 more
europepmc   +1 more source

Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges

Journal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
ABSTRACT Background Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders commonly driven by mutations in JAK2, MPL, or CALR. Because routine CALR assays are largely optimized for the canonical Type 1 and Type 2 exon 9 variants, rare noncanonical mutations may be missed, creating diagnostic challenges.
Teresa Maltese, Giuseppina Raffa, Fabio Stagno, Rossana Leanza, Paola Barone, Alessandro Allegra, Teresa Pollicino   +6 more
wiley   +1 more source